Literature DB >> 18097155

Biomarkers for early detection of Alzheimer pathology.

C M Clark1, C Davatzikos, A Borthakur, A Newberg, S Leight, V M-Y Lee, J Q Trojanowski.   

Abstract

The increasing prevalence of Alzheimer's disease and the devastating consequences of late-life dementia motivates the drive to develop diagnostic biomarkers to reliably identify the pathology associated with this disorder. Strategies to accomplish this include the detection of altered levels of tau and amyloid in cerebrospinal fluid, the use of structural MRI to identify disease-specific patterns of regional atrophy and MRI T(1)rho to detect disease-related macromolecular protein aggregation, and the direct imaging of amyloid deposits using positron emission tomography and single photon emission computerized tomography. Success will facilitate the ability to reliably diagnose Alzheimer's disease while the symptoms of brain failure are mild and may provide objective measures of disease-modifying treatment efficacy.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18097155      PMCID： PMC2866153          DOI： 10.1159/000109754

Source DB:  PubMed          Journal:  Neurosignals        ISSN： 1424-862X


  35 in total

1.  SPECT perfusion imaging in the diagnosis of Alzheimer's disease: a clinical-pathologic study.

Authors:  W Jagust; R Thisted; M D Devous; R Van Heertum; H Mayberg; K Jobst; A D Smith; N Borys
Journal:  Neurology       Date:  2001-04-10       Impact factor: 9.910

2.  Global prevalence of dementia: a Delphi consensus study.

Authors:  Cleusa P Ferri; Martin Prince; Carol Brayne; Henry Brodaty; Laura Fratiglioni; Mary Ganguli; Kathleen Hall; Kazuo Hasegawa; Hugh Hendrie; Yueqin Huang; Anthony Jorm; Colin Mathers; Paulo R Menezes; Elizabeth Rimmer; Marcia Scazufca
Journal:  Lancet       Date:  2005-12-17       Impact factor: 79.321

3.  F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain.

Authors:  Wei Zhang; Shunichi Oya; Mei-Ping Kung; Catherine Hou; Donna L Maier; Hank F Kung
Journal:  Nucl Med Biol       Date:  2005-11       Impact factor: 2.408

4.  Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy.

Authors:  H Benveniste; G Einstein; K R Kim; C Hulette; G A Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

5.  MRI predictors of risk of incident Alzheimer disease: a longitudinal study.

Authors:  T R Stoub; M Bulgakova; S Leurgans; D A Bennett; D Fleischman; D A Turner; L deToledo-Morrell
Journal:  Neurology       Date:  2005-05-10       Impact factor: 9.910

6.  Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging.

Authors:  Gaël Chetelat; Jean-Claude Baron
Journal:  Neuroimage       Date:  2003-02       Impact factor: 6.556

7.  Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.

Authors:  Niels Andreasen; Eugeen Vanmechelen; Hugo Vanderstichele; Pia Davidsson; Kaj Blennow
Journal:  Acta Neurol Scand Suppl       Date:  2003

8.  Alzheimer disease in the US population: prevalence estimates using the 2000 census.

Authors:  Liesi E Hebert; Paul A Scherr; Julia L Bienias; David A Bennett; Denis A Evans
Journal:  Arch Neurol       Date:  2003-08

9.  CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects.

Authors:  K Buerger; S J Teipel; R Zinkowski; K Blennow; H Arai; R Engel; K Hofmann-Kiefer; C McCulloch; U Ptok; R Heun; N Andreasen; J DeBernardis; D Kerkman; H- J Moeller; P Davies; H Hampel
Journal:  Neurology       Date:  2002-08-27       Impact factor: 9.910

10.  Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study.

Authors:  Hilary A Archer; Paul Edison; David J Brooks; Jo Barnes; Chris Frost; Tom Yeatman; Nick C Fox; Martin N Rossor
Journal:  Ann Neurol       Date:  2006-07       Impact factor: 10.422
View more
  43 in total

Review 1.  The Alzheimer's disease neuroimaging initiative: progress report and future plans.

Authors:  Michael W Weiner; Paul S Aisen; Clifford R Jack; William J Jagust; John Q Trojanowski; Leslie Shaw; Andrew J Saykin; John C Morris; Nigel Cairns; Laurel A Beckett; Arthur Toga; Robert Green; Sarah Walter; Holly Soares; Peter Snyder; Eric Siemers; William Potter; Patricia E Cole; Mark Schmidt
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

Review 2.  The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Enchi Liu; John C Morris; Ronald C Petersen; Andrew J Saykin; Mark E Schmidt; Leslie Shaw; Judith A Siuciak; Holly Soares; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2011-11-02       Impact factor: 21.566

3.  Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease.

Authors:  Victor L Villemagne; Keyla A Perez; Kerryn E Pike; W Mei Kok; Christopher C Rowe; Anthony R White; Pierrick Bourgeat; Olivier Salvado; Justin Bedo; Craig A Hutton; Noel G Faux; Colin L Masters; Kevin J Barnham
Journal:  J Neurosci       Date:  2010-05-05       Impact factor: 6.167

4.  Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment.

Authors:  William T Hu; Alice Chen-Plotkin; Steven E Arnold; Murray Grossman; Christopher M Clark; Leslie M Shaw; Eve Pickering; Max Kuhn; Yu Chen; Leo McCluskey; Lauren Elman; Jason Karlawish; Howard I Hurtig; Andrew Siderowf; Virginia M-Y Lee; Holly Soares; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2010-03-16       Impact factor: 17.088

Review 5.  Biomarkers for cognitive impairment in Parkinson disease.

Authors:  Min Shi; Bertrand R Huber; Jing Zhang
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

6.  Lifestyle and genetic contributions to cognitive decline and hippocampal structure and function in healthy aging.

Authors:  John L Woodard; Michael A Sugarman; Kristy A Nielson; J Carson Smith; Michael Seidenberg; Sally Durgerian; Alissa Butts; Nathan Hantke; Melissa Lancaster; Monica A Matthews; Stephen M Rao
Journal:  Curr Alzheimer Res       Date:  2012-05       Impact factor: 3.498

7.  CSF biomarkers in different phenotypes of Parkinson disease.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2011-11-08       Impact factor: 3.575

8.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

9.  Quantitative plasma proteomic profiling identifies the vitamin E binding protein afamin as a potential pathogenic factor in SIV induced CNS disease.

Authors:  Gurudutt Pendyala; Sunia A Trauger; Gary Siuzdak; Howard S Fox
Journal:  J Proteome Res       Date:  2010-01       Impact factor: 4.466

Review 10.  Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics.

Authors:  Yahui Liu; Hong Qing; Yulin Deng
Journal:  Int J Mol Sci       Date:  2014-05-06       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.